文献速递MDS 与骨髓增殖性肿瘤白血病

骨髓增生异常综合征胚系易感性的真实世界研究

Real-world investigation of germ line predisposition to myelodysplastic syndromes.
PubMed 文献 · Blood Adv · 2026-01-01

该研究在716例未选择的MDS评估患者中,基于诊断性靶向测序识别等位基因频率≥35%的CEBPA、DDX41、ETV6、GATA2和RUNX1变异,并对可行者进行胚系验证。共87例(12.2%)检出98个变异,最终19例(2.7%)确认致病/可能致病胚系变异,多数为DDX41(73.7%)。结合年轻患者病历回顾,整体易感性检出率升至3.4%,<50岁患者达16.7%。

要点

  • 诊断性靶向测序后系统胚系随访在典型成人MDS门诊可检出近3%的胚系易感性。
  • 检出的致病/可能致病胚系变异以DDX41为主(73.7%),其余涉及RUNX1、GATA2和ETV6。
  • 年轻患者(<50岁)需对诊断性靶向测序未常规评估的基因进行胚系检测。

核心结论

  • 诊断性靶向测序后系统胚系随访在未选择的MDS评估人群中可行,近3%患者检出胚系易感性。
  • 年轻患者需额外检测诊断性靶向测序未常规覆盖的易感基因。

研究设计与样本

  • 真实世界队列研究,纳入716例因MDS评估的患者,中位年龄74岁。
  • 分析诊断性靶向测序中CEBPA、DDX41、ETV6、GATA2和RUNX1等位基因频率≥35%的变异,并对62例进行胚系验证,25例无生物样本者回顾病历。

主要发现

  • 87例(12.2%)患者共检出98个候选变异。
  • 19例(2.7%)确认致病/可能致病胚系变异,其中DDX41占73.7%,RUNX1、GATA2和ETV6分别占10.5%、10.5%和5.3%。
  • 致病/可能致病胚系变异患者诊断中位年龄73岁,男女比例3.75:1,68.4%为MDS-EB1或MDS-EB2,95%核型正常。
  • 年轻患者(<50岁)病历回顾额外发现5例其他基因胚系易感性,整体检出率升至3.4%,<50岁患者达16.7%。

关键数值与推荐

  • 候选变异筛选标准:CEBPA、DDX41、ETV6、GATA2和RUNX1变异且等位基因频率≥35%。
  • 各基因胚系转化率介于5.4%至93.3%之间。

临床怎么用

  • 对MDS患者诊断性靶向测序中符合阈值的高频变异应系统开展胚系验证。
  • 年轻MDS患者即使诊断性靶向测序阴性,也应考虑检测未常规覆盖的胚系易感基因。

局限性

  • 25例无生物样本者仅回顾病历,可能低估胚系变异检出。
  • 年轻患者中其他基因的胚系易感性基于病历回顾,非系统检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follow-up of potential germ line variants revealed by diagnostic targeted sequencing (TS) for myelodysplastic syndromes (MDS) has been proposed by clinical guidelines. However, their feasibility and clinical yield in routine MDS practice remain uncertain. We evaluated the real-world applicability of systematic germ line follow-up in an unselected cohort of 716 patients (median age, 74 years) evaluated for MDS. Their diagnostic TS data were analyzed to identify variants in CEBPA, DDX41, ETV6, GATA2, and RUNX1 with a variant allele frequency of ≥35%. In total, 98 variants were identified in 87 (12.2%) patients. Germ line investigation was possible for 62 patients; for the remaining 25 without biobanked material, medical charts were reviewed. We identified pathogenic/likely pathogenic (P/LP) germ line variants in 19 patients (2.7%). Most P/LP variants were found in DDX41 (73.7%), followed by 10.5%, 10.5%, and 5.3% in RUNX1, GATA2, and ETV6, respectively, with germ line conversion rates between 5.4% and 93.3%. Patients with P/LP variants had a median age at diagnosis of 73 years, with male predominance (3.75:1). Most patients were diagnosed with MDS-excess blasts-1 (MDS-EB1) or MDS-EB2 (68.4%) and had normal cytogenetics (95%). A review of medical charts in younger patients (aged <50 years) revealed germ line predisposition in other genes in an additional 5 patients, revisiting the prevalence of predisposition to 3.4% overall and to 16.7% in those aged <50 years. Our results show that systematic germ line follow-up after diagnostic TS succeeds in identifying predisposition in nearly 3% of patients at a typical adult MDS clinic. Germ line testing for genes not routinely assessed by diagnostic TS is required in younger patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tranberg A, Creignou M, Mortera Blanco T, et al. Real-world investigation of germ line predisposition to myelodysplastic syndromes. Blood Adv. 2026. PMID: 42532513. doi:10.1182/bloodadvances.2026019942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。